Watch one bispecific go from target to lead.
Follow Program Meridian, a CD3 × tumor-antigen T-cell engager, through six short chapters on one connected record. Every stage builds on the data the last one produced.
Meet Program Meridian
A quick orientation before the walkthroughs: the thesis, the molecule, and the path from two antigens to a validated lead. One connected record, six chapters, each building on the data the one before it produced.
Six chapters, one connected record
Every chapter is a silent, captioned screen walkthrough on the same seeded program. Watch in order, or jump to the stage you care about.
Set the target pair
Stand up the program against its two antigens on one record: the CD3 arm, the tumor-antigen arm, a schedule, and the target product profiles everything downstream will be scored against.
You'll see: the program record, both targets, and the campaign plan.
Find both arms
Discover, sequence, and triage the two parental binders in one place: clones ranked by NGS enrichment, germline V(D)J and IMGT annotation, sequence liabilities flagged, and a colored alignment with a consensus logo.
You'll see: discovery, NGS, and annotated sequences for each arm.
Build the bispecific
Turn two arms into a molecule, then a panel. Design the knobs-into-holes format on the canvas, pair every anti-CD3 clone with every anti-TAA clone, and enumerate the whole panel of variants, each already a real expression construct.
You'll see: the biomolecule designer, combinatorial paneling, and per-chain vector construction.
Express & QC the panel
Co-express the panel and review each lot for titer, purity, and assembly, every lot linked to the construct it came from and ready to test.
You'll see: the lot review, with QC read per variant.
Prove it binds and kills
Test every variant the same way: kinetics on both arms, a Hill 4PL fit and an EC50 for each variant, twelve killing curves side by side, and a developability read on purity and aggregation.
You'll see: binding kinetics, the dose-response killing curves, and SEC purity.
Pick the lead
Rank the twelve variants against the target product profile on the data your teams produced, advance the winner into an in-vivo study, and open the same live view leadership sees.
You'll see: the scored ranking, the in-vivo tumor-growth curve, and the leadership dashboard.
From two binders to a validated lead
Target to lead, on one record. Discovery, a bispecific panel, expression and QC, binding and killing, and an in-vivo readout, all connected, each stage standing on the data the last one produced.
Hear what others are saying about StackWave
"StackWave gives us confidence in our leads by collecting all of the data about our potential therapeutics in one place and making that data actionable by allowing us to compare antibodies of interest."
"I worked with StackWave for ~4 years at my previous job to implement our LIMS. It was a great learning experience. We put in place an incredible system for our entire workflow, from plasmid registration to in-vivo study data registration."
"StackWave’s Platform allowed us to collaborate on our in-vivo studies in a web browser at home... I would highly recommend StackWave for therapeutic discovery teams looking to improve collaboration between teams."